Prochymal's Canadian Nod Marks Stem Cell Milestone

LONDON – The timing could not have been better. The international stem cell community getting together in London was able to applaud the breakthrough signified by Health Canada's approval of Prochymal, Osiris Therapeutics Inc.'s allogeneic stem cell treatment for graft-vs.-host disease, and rejoice in the knowledge that there is light at the end of the regulatory tunnel.